Phase II Trial to Evaluate The Efficacy of Obinutuzumab (RO5072759) + Bendamustine Treatment in Patients With Refractory Or Relapsed Chronic Lymphocytic Leukemia
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 22 Jun 2017
At a glance
- Drugs Obinutuzumab (Primary) ; Bendamustine
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- Sponsors Roche
- 14 Jun 2017 Planned End Date changed from 1 Oct 2018 to 19 Nov 2018.
- 14 Jun 2017 Planned primary completion date changed from 1 Oct 2018 to 19 Nov 2018.
- 03 Oct 2016 Status changed from recruiting to active, no longer recruiting.